Document is current
Any future updates will be listed below
-
Authors
Sztupinszki, Zsofia
Fiam, Regina
Pipek, Orsolya
Diossy, Miklos
Börcsök, Judit
Prosz, Aurel
Csabai, Istvan
Szallasi, Zoltan
-
Funding
Funding for this research was provided by:
Ovarian Cancer Research Alliance (CRDGAI-2025-3-1992, CRDGAI-2025-3-1992)
Breast Cancer Research Foundation (BCRF-23-159)
Kræftens Bekæmpelse (R325-A18809 and R342-A19788)
Sundhed og Sygdom, Det Frie Forskningsråd (2034-00205B)
Basser Foundation
National Institutes of Health (1 P01 CA228696-01A1)
- License Information
-
More Information
Article History
Received: 17 March 2025
Accepted: 6 June 2025
First Online: 20 June 2025
Competing interests
: Z. Szallasi is an inventor on a patent used in the myChoice HRD assay. Z.Szallasi, Zs. Sztupinszki, J.B., and M.D. are co-inventors in an institutional patent, detecting NER-deficiency from clinical samples.
